CD274 and neoplasm: As CI treatment, especially anti-PD(L)1 mAb, reinvigorates T-cells, the low number of tumor-infiltrating T-cells (TILs) in MPM might explain the relatively low response rates found in clinical trials investigating anti-PD1/PD-L1 treatment (23).